The study, published Aug. 6 in Cell Reports Medicine, addresses one of the central challenges in oncology: two tumors that appear similar under a microscope can respond very differently to the same therapy. Breast cancer treatment decisions are increasingly guided by biomarkers, such as hormone-receptor status, HER2 amplification and DNA-repair alterations, but these measurements do not always reveal which drug will work best in a particular patient. The UCSF team investigated whether living tumor models could provide a functional test of treatment response alongside genomic and clinical information.

To create the organoids, researchers placed cells taken from patient tumors into a specialized gel engineered to support the biological conditions of the original cancer. Over several weeks, the cells organized into compact, three-dimensional structures containing hundreds or thousands of cells. Unlike conventional cancer cell lines grown as flat layers, organoids preserve aspects of tumor architecture and retain many of the molecular features found in the tissue from which they were derived. Their small size also makes it possible to expose large numbers of organoids to multiple drugs in parallel.

The team established a biobank of organoids from early-stage invasive breast cancers and compared their behavior with clinical information from patients enrolled in the I-SPY2 trial. I-SPY2 is designed to accelerate the testing of therapies for high-risk breast cancer by evaluating several treatments simultaneously in biologically defined patient groups. The trial has generated “response predictive subtypes,” molecular classifications intended to estimate how tumors will respond to therapies such as immunotherapy, platinum chemotherapy, PARP inhibitors and dual-HER2-targeted drugs.

Using these predictive subtypes and additional tumor biomarkers, the researchers built a computational framework to forecast how individual organoids would react to specific treatments. They then tested the predictions experimentally. The model was especially evaluated in organoids derived from triple-negative breast cancers, a subtype that lacks estrogen and progesterone receptors and does not show elevated levels of HER2. Because triple-negative tumors have fewer established molecular targets and can rapidly develop treatment resistance, patients are often treated with intensive chemotherapy, including platinum-based drugs.

One treatment combination examined in the study was veliparib plus platinum chemotherapy, referred to as VP. Veliparib inhibits PARP proteins, which help repair certain forms of DNA damage, while platinum drugs damage DNA directly. The combination is intended to overwhelm the tumor’s repair machinery, but not every triple-negative tumor is vulnerable to it. Among the organoids, the model identified one sample, designated TORG40, as having a particularly high likelihood of resistance. Laboratory experiments subsequently confirmed that TORG40 showed limited sensitivity to VP, providing a test of the prediction system.

The researchers then used TORG40 to conduct a high-throughput drug screen involving 386 small-molecule inhibitors. The screen highlighted ABT-263, a compound that targets proteins involved in cellular survival and can promote the removal of damaged or stressed cells. When ABT-263 was combined with cisplatin, a platinum chemotherapy drug, the treatment produced a markedly stronger effect against the resistant TORG40 organoid than either agent alone. The result suggests that functional drug screening may uncover vulnerabilities that are not obvious from standard biomarkers, although the combination remains an experimental finding rather than an established treatment.

The organoid experiments also identified HSP90 inhibitors as potential candidates for further study. HSP90 is a molecular chaperone that helps stabilize and maintain numerous proteins, including proteins involved in cancer growth and survival. Blocking HSP90 can disrupt several signaling pathways at once, which may be useful in tumors driven by complex or overlapping mechanisms. The researchers linked the organoid findings to a subset of I-SPY patients who appeared to respond more favorably to drugs in this class, offering an example of how laboratory observations can be connected back to clinical trial data.

The investigators emphasize that the organoids do not reproduce the full environment of a tumor inside the body. They lack blood vessels, immune cells, stromal tissue and the broader organ systems that influence how cancer cells receive signals and how drugs are distributed. The study also did not determine whether organoid-guided treatment decisions would improve patient outcomes over months or years. Even so, the findings support a “reverse translational” strategy in which clinical trial data are used to generate laboratory predictions, and organoid experiments are then used to discover and prioritize therapies. With further validation in prospective clinical studies, patient-derived organoids could eventually become a practical bridge between molecular biomarkers and more individualized breast cancer treatment.

Subject of Research: Lab-produced tissue samples

Article Title: Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer

News Publication Date: 6-Aug-2026

Web References: https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(26)00390-3

References: DOI: 10.1016/j.xcrm.2026.102973

Keywords: Breast cancer, triple-negative breast cancer, patient-derived organoids, tumor organoids, personalized medicine, biomarkers, drug resistance, combination therapy, cisplatin, veliparib, PARP inhibitors, HSP90 inhibitors, I-SPY2 trial, precision oncology

The OPTIMA trial—standing for Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis—represents one of the most extensive international breast cancer studies to date. Encompassing over 4,400 patients from multiple continents including the UK, Norway, Sweden, Australia, New Zealand, and Thailand, the study rigorously assessed how gene expression profiling could refine therapeutic decisions in early-stage breast cancer management.

At the core of OPTIMA’s methodology lies the Prosigna test, a robust genomic assay developed by Veracyte. This diagnostic tool analyzes the activity of a panel of cancer-related genes within tumor tissue samples, quantifying the risk of disease recurrence. Unique in its compatibility with standard NHS laboratory equipment, the test represents a scalable innovation in personalized oncology, capable of being performed on both surgical specimens and minimally invasive biopsy samples.

Participants in the OPTIMA trial consisted of men and women aged 40 years and older diagnosed with hormone-sensitive breast cancer, many presenting with nodal involvement, which traditionally predicates the recommendation for adjuvant chemotherapy alongside hormone therapy. The trial randomized patients into two arms: the conventional treatment group receiving chemotherapy plus hormone therapy, and the test-directed group where treatment was guided by Prosigna scores. Patients exhibiting high genomic risk scores (above 60) were administered both chemotherapy and hormone therapy, while those with low scores (60 or below) were treated exclusively with hormone therapy.

The trial’s principal objective centered on determining whether tailoring treatment based on genomic risk could reduce chemotherapy utilization without sacrificing disease-free survival. Clinical outcomes evaluated five years post-treatment illuminated a striking concordance in recurrence-free survival rates between chemotherapy recipients and those spared chemotherapy within the low-risk subgroup. Specifically, 94.8% of the chemotherapy group and 93.6% of the hormone-only group remained alive and free from cancer relapse, indicating an insignificant difference well within the pre-established 3% non-inferiority threshold.

Statistical analyses suggest that the actual benefit of chemotherapy in low Prosigna score patients is minimal, estimating that only up to 2% would gain from chemotherapy administration. This pivotal insight reframes the risk-benefit calculus for this substantial patient cohort, promising improved quality of life by circumventing adverse effects such as immunosuppression, neuropathy, and cognitive impairment traditionally associated with chemotherapy.

Importantly, the trial extended its scrutiny across demographic and clinical variables. The evidence indicated consistent outcomes irrespective of menopausal status, including premenopausal patients whose ovarian function was transiently suppressed as part of hormone therapy, and across varying extents of lymph node involvement. While male participants were incorporated, their numbers were insufficient for robust subgroup conclusions, necessitating further research.

The implications of OPTIMA’s findings extend well beyond individual patient care. Health systems stand to gain from more judicious allocation of resources by reducing unnecessary chemotherapy use. The anticipated impact on NHS practice guidelines and reimbursement policies is underscored by ongoing evaluations of cost-effectiveness and survival outcomes across the broader trial population. Discussions with national healthcare bodies such as the National Institute for Health and Care Excellence (NICE) are underway to facilitate wider access to Prosigna testing within routine clinical workflows.

Beyond statistics and health economics, the OPTIMA trial has imparted tangible benefits to patients like Karen Bonham, a 64-year-old from Cardiff. Diagnosed with hormone-sensitive breast cancer with nodal spread, she faced the daunting prospect of chemotherapy until Prosigna testing guided her treatment away from this path. Her experience epitomizes the profound psychological and physical relief afforded by precision medicine, enabling her to return to an active, cancer-free life nearly a decade later.

The success of the OPTIMA trial signals a paradigm shift towards integrating tumor biology with clinical decision-making, elevating personalized medicine from concept to practice. This approach transcends traditional reliance on histopathological features alone, fostering treatments that are intricately calibrated to each patient’s molecular cancer profile.

While the study solidly establishes the safety of omitting chemotherapy in patients aged 40 and older with low-risk genomic scores, it leaves open critical questions regarding younger populations. Investigations to expand genomic testing validation among premenopausal women under 40 are underway, with results anticipated in coming years.

The confluence of cutting-edge genomic technology, rigorous clinical trial design, and international collaboration embodied in OPTIMA exemplifies the future of oncological care. Through refined treatment stratification, it aims to diminish overtreatment, enhance patient well-being, and optimize healthcare delivery on a global scale.

This innovative research not only augments our understanding of breast cancer biology but also offers a tangible tool to translate that knowledge into practice—empowering clinicians and patients to navigate treatment pathways with greater confidence and hope.

Subject of Research: People
Article Title: Genomic Testing Enables Thousands to Forego Chemotherapy in Early-Stage Breast Cancer: Insights from the OPTIMA Trial
News Publication Date: 2026 (ASCO Annual Meeting 2026)
Web References:

• UCL Cancer Institute: www.ucl.ac.uk
• OPTIMA trial main page (UCL)
• American Society of Clinical Oncology (ASCO) Annual Meeting 2026
  References:
• OPTIMA Trial Data, University College London, 2026
• Prosigna Assay Technical Documentation, Veracyte Inc.
  Image Credits: Karen Bonham (Patient)
  Keywords: Breast cancer, Hormone-sensitive, Chemotherapy avoidance, Genomic testing, Prosigna test, Personalized medicine, Clinical trial, Oncology, Tumor biology

Tamoxifen functions primarily by inhibiting the proliferative effects of estrogen on hormone-sensitive breast cancer cells, preventing the hormone from binding to its receptor and thereby dampening tumor growth. However, tamoxifen’s effectiveness hinges on its metabolic activation within the body into an active metabolite known as (Z)-endoxifen. This biotransformation process is predominantly catalyzed by the enzyme cytochrome P450 2D6 (CYP2D6). Genetic polymorphisms affecting CYP2D6 activity result in significant interindividual variability in tamoxifen metabolism, which can dramatically influence clinical outcomes. Approximately one-third of patients demonstrate a suboptimal conversion rate due to compromised CYP2D6 function, which is associated with a heightened risk of cancer recurrence.

In response to this challenge, the IKP has pioneered TAMENDOX, an innovative therapeutic strategy designed to directly supplement (Z)-endoxifen levels in patients exhibiting poor metabolic conversion. This approach circumvents the enzymatic deficiency by delivering the metabolite essential for tamoxifen’s anti-cancer activity, thereby restoring drug efficacy through a precision medicine lens. The clinical implications are profound, offering a solution to a long-standing pharmacogenetic obstacle in breast cancer treatment.

This multicentric study, coordinated by the IKP and involving 38 medical clinics across Germany, enrolled 235 patients diagnosed with early-stage hormone receptor-positive breast cancer. Participants were stratified based on their CYP2D6 genetic profile and plasma drug levels into two treatment arms: tamoxifen monotherapy and combination therapy wherein (Z)-endoxifen was administered alongside tamoxifen. Over a six-week treatment window, pharmacokinetic analyses revealed that patients receiving the combination regimen achieved blood concentrations of the active metabolite comparable to those with genetically normal CYP2D6 metabolism on tamoxifen alone. This demonstrates that TAMENDOX can effectively normalize drug exposure and potentially improve therapeutic outcomes.

The clinical results underscore the potential of targeted pharmacogenetic interventions in oncologic therapeutics. By tailoring hormone treatment to the metabolic capacity of individual patients, TAMENDOX embodies the principles of personalized medicine, directly translating genomic insights into enhanced drug efficacy. Professor Matthias Schwab, the institute’s director, emphasizes this milestone as the first viable solution to the persistent issue of tamoxifen’s limited effectiveness in a subset of patients, highlighting how such innovations can substantially augment existing treatment paradigms with tangible benefits for patient care.

Safety and tolerability are paramount in any oncological intervention, and TAMENDOX demonstrates a reassuring profile. The combination therapy was well tolerated across the patient cohort, with adverse events being minimal and comparable to those observed in patients receiving standard tamoxifen monotherapy. This favorable safety profile reinforces the clinical feasibility of this approach for broader application in hormone receptor-positive breast cancer.

Premenopausal women, who often face constrained therapeutic options due to the limitations of alternatives like aromatase inhibitors, stand to gain significant advantages from this novel treatment paradigm. By enhancing the efficacy of tamoxifen without introducing prohibitive side effects, TAMENDOX offers a promising expansion of the therapeutic arsenal available for this vulnerable patient population, addressing a critical unmet need in breast cancer management.

The implications of this research extend beyond immediate clinical application, potentially informing regulatory pathways for drug approval and integration into clinical guidelines. The IKP is actively pursuing the development of a regulatory framework to facilitate the approval and clinical dissemination of TAMENDOX. This forward-looking initiative aims to translate the clinical trial’s compelling evidence into accessible, standardized treatment options that can redefine breast cancer therapy on a global scale.

The TAMENDOX study exemplifies the convergence of pharmacogenetics, clinical pharmacology, and oncology, illustrating how precision medicine transforms once intractable treatment limitations into solvable challenges. By leveraging detailed genetic and pharmacokinetic profiling, this approach personalizes cancer therapy, maximizing drug effectiveness while minimizing unnecessary toxicity. Such strategies herald a new era in cancer therapeutics, where personalized adjustments can optimize outcomes based on the unique biologic characteristics of each patient.

Beyond the immediate application to breast cancer, the mechanisms elucidated by TAMENDOX’s development have broader implications for other hormonally driven cancers and conditions where drug metabolism variability impacts treatment response. This paradigm of supplementing active metabolites or adjusting dosages based on genetic and metabolic profiling could serve as a model for future drug development and personalized treatment optimization in diverse medical fields.

As the IKP advances the TAMENDOX initiative towards regulatory submission and broader clinical use, the oncology community anticipates a transformative impact on hormone receptor-positive breast cancer management. The integration of genetic insights into routine clinical practice not only improves efficacy but also aligns with the evolving vision of patient-centric, precision oncology that prioritizes tailored interventions for maximal therapeutic benefit.

In conclusion, the TAMENDOX clinical study marks a significant leap forward in breast cancer therapy by addressing a critical pharmacogenetic limitation in tamoxifen metabolism. This innovative combination therapy exemplifies the power of personalized medicine to refine existing treatments, offering renewed hope to patients and clinicians alike in the battle against the world’s most common cancer among women.

Subject of Research: Development of personalized hormone therapy for breast cancer based on pharmacogenetics.

Article Title: Precision Enhancement of Tamoxifen Efficacy Through (Z)-Endoxifen Supplementation in Hormone Receptor-Positive Breast Cancer

News Publication Date: 2024

Web References:

• WHO Breast Cancer Fact Sheet: https://www.who.int/news-room/fact-sheets/detail/breast-cancer
• DOI for Clinical Study: http://dx.doi.org/10.1158/1078-0432.ccr-25-2103

References:

• Clinical Cancer Research Journal Article DOI: 10.1158/1078-0432.ccr-25-2103

Keywords: Breast cancer, tamoxifen, (Z)-endoxifen, CYP2D6, pharmacogenetics, personalized medicine, hormone therapy, clinical pharmacology, translational medicine, cancer treatment, hormone receptor-positive breast cancer, breast cancer medication

HER2, or human epidermal growth factor receptor 2, is a well-known biomarker in breast cancer. Detection of HER2 overexpression via IHC informs treatment decisions, including the use of targeted therapies like trastuzumab and pertuzumab, which significantly improve patient prognosis. However, despite advances in antibody technology, variability remains a concern. The inconsistency often stems from the structural complexity of HER2 in its different forms—particularly its existence as both monomers and dimers within cancer cells. These conformational states can obscure antibody binding sites, potentially leading to under-detection or misclassification of HER2 status, which profoundly affects clinical outcomes.

The innovative strategy detailed in this study pivots on the structural analysis of HER2 and its interaction with existing diagnostic antibodies. The researchers meticulously aligned the molecular configuration of HER2 heterodimers with the binding regions of trastuzumab and pertuzumab. Remarkably, both antibodies targeted nearly identical regions of the HER2 molecule, suggesting a steric hindrance—spatial interference—that could limit antibody accessibility when HER2 is in dimeric form. This insight catalyzed the search for alternative molecular probes capable of circumventing this limitation.

Taking inspiration from nature’s toolkit, the investigators turned to HER2-binding affibodies and nanobodies, small engineered proteins known for their high affinity and unique binding capabilities at sites distinct from traditional antibodies. They designed a fusion protein combining these two entities, termed Nby-Aby, capable of simultaneously targeting separate regions on the HER2 receptor. This dual-targeting mechanism ensures that the fusion protein binds effectively even when HER2 molecules dimerize, reducing the impact of steric hindrance that hampers conventional antibody flexibility.

To further enhance detection, the researchers incorporated these binding proteins into human heavy chain ferritin (HFn) nanoparticles, creating novel constructs such as Nby-HFn and Aby-HFn. These nanoparticles serve as scaffolds presenting multiple binding moieties, thereby increasing avidity and detection robustness. The use of ferritin-based nanoparticles, with their biocompatibility and structural stability, offers a promising platform for improving diagnostic reagents’ performance within the complex environment of tissue samples.

Validation of this avant-garde technology was performed using breast cancer tissue microarrays (TMAs), offering a high-throughput format to compare the new Nby-Aby assay against conventional HER2 antibodies. The results were illuminating: the dual-targeting Nby-Aby assay demonstrated substantially enhanced sensitivity in detecting HER2-positive cells across a broad spectrum of tissue samples. Enhanced detection was particularly notable in cases previously categorized as HER2-low or negative, suggesting that some tumors might be underdiagnosed using existing methodologies.

This refined detection capacity transcends mere incremental improvement—it signals a paradigm shift in how diagnostics can harness molecular engineering to tackle fundamental biological challenges. The dual-targeting principle effectively unveils HER2 epitopes occluded in dimeric formations, shedding light on cancer cells that may have evaded accurate classification. This not only impacts initial diagnosis but also has downstream implications for treatment stratification, patient monitoring, and outcome prediction.

The study’s findings challenge the current one-size-fits-all approach to IHC assays by underscoring the need to address protein conformation dynamics during antibody-based detection. By leveraging the natural specificity and modularity of nanobodies and affibodies, the researchers present a scalable and versatile platform adaptable to other receptor systems that may suffer from similar steric challenges.

Beyond diagnostic enhancement, this work opens the door to the potential development of therapeutic agents that exploit dual-binding mechanisms. Such agents could more effectively interfere with HER2 signaling pathways by simultaneously engaging multiple receptor sites, potentially overcoming resistance mechanisms linked to receptor dimerization. Moreover, nanoparticles like HFn could serve as delivery vehicles, combining diagnostic and therapeutic functionalities into so-called theranostic agents.

Importantly, the methodological rigor demonstrated in this study plays a pivotal role in its translational promise. Detailed structural alignments informed the design of fusion proteins, while robust immunohistochemical assessments across numerous patient-derived samples validated clinical relevance. This integrative approach, weaving molecular biophysics with clinical pathology, exemplifies the interdisciplinary innovation needed in cancer research.

The implications of improved HER2 detection extend beyond breast cancer. HER2 aberrations occur in other malignancies such as gastric, ovarian, and lung cancers, where precise biomarker evaluation critically guides therapy. The methodological advancements in overcoming steric hindrance and dual-targeting can potentially be adapted to these tumor types, amplifying the impact of this discovery.

From a technical perspective, the utilization of nanobodies derived from camelid antibodies offers excellent tissue penetration due to their small size, while affibodies provide high affinity and specificity. Their combination in a single fusion protein capitalizes on these complementary strengths, setting a precedent for next-generation diagnostic reagents. Furthermore, ferritin nanoparticles offer a robust and biocompatible scaffold, which could facilitate enhanced signal amplification in IHC staining protocols.

The researchers’ ability to significantly elevate HER2 scores in tissue microarrays compared to traditional antibody detection indicates that false negatives in current diagnostic workflows might be more common than previously acknowledged. Consequently, implementing such enhanced detection strategies could refine patient selection for HER2-targeted therapies, ultimately improving clinical outcomes through personalized medicine.

In conclusion, this pioneering study underscores the value of molecular engineering and structural biology insights in addressing long-standing diagnostic challenges. The novel dual-targeting Nby-Aby fusion protein and its nanoparticle conjugates represent a formidable advance in HER2 IHC testing. By overcoming the steric hindrance inherent in dimeric HER2 receptors, this approach enhances detection sensitivity, offering the promise of more accurate diagnostics and better-informed treatment decisions for breast cancer patients worldwide.

As this technology moves toward broader clinical adoption, further exploration into its applicability across diverse cancer types and integration with existing diagnostic platforms will be critical. The melding of molecular precision with clinical pathology heralds a new chapter in cancer diagnostics, one that promises to improve lives through smarter detection and tailored therapies.

Subject of Research: HER2 immunohistochemistry (IHC) detection improvement in breast cancer diagnosis through dual-targeting and steric hindrance resolution.

Article Title: Dual-targeting and steric hindrance resolution in HER2 IHC: a novel approach to improve diagnostic sensitivity

Article References:
Luo, L., Zhang, X., Chen, L. et al. Dual-targeting and steric hindrance resolution in HER2 IHC: a novel approach to improve diagnostic sensitivity. BMC Cancer 25, 1231 (2025). https://doi.org/10.1186/s12885-025-14553-7

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14553-7